This was a relatively small and first exploratory study of zervimesine in DLB and all results will require replication in larger controlled studies; however, it is notable that across all symptom domains surveyed, there was a clear trend toward slowed progression in the zervimesine treatment group.
← all excerpts
Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).
1
—
—